Drug Profile
Elsiglutide - Zealand Pharma
Alternative Names: ZP-1846Latest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Helsinn; Zealand Pharma
- Class Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diarrhoea
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-II for Diarrhoea (Prevention, Chemotherapy-induced) in Ukraine, Poland, Belarus, Czech Republic, Germany, Russia, Hungary, Bulgaria, Romania (SC) (Zealand Pharma pipeline, September 2021)
- 15 Feb 2019 Elsiglutide is still in phase II trials for Diarrhoea in Belarus, Bulgaria, Czech Republic, Germany, Hungary, Poland, Russia and Ukraine (Zealand Pharma website, February 2019)
- 12 Jun 2017 Helsinn Healthcare returns its worldwide licensing rights to elsiglutide to Zealand Pharma